Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Drugs can save African infants' lives

Researchers at the University of Sydney have found the combined intake of iron-folic acid supplements with World Health Organisation (WHO)-endorsed anti-malarial drugs during pregnancy could reduce early infant mortality in sub-Saharan Africa by a quarter.

22 Jul 2010

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

Affymax completes sale of all auction rate securities held by UBS

Affymax, Inc. today announced the completion of the sale at par value of all auction rate securities held by UBS AG and its affiliates in a transaction which generated net proceeds of $5.0 million to Affymax, after payment of $5.4 million from the proceeds to retire a loan due to UBS. From April 1, 2010 through June 30, 2010, $3.7 million of the UBS ARS were settled at par value resulting in a corresponding reduction in the balance of UBS ARS and related loan since the first quarter 2010. The company now has no debt liability on its balance sheet.

20 Jul 2010

Researchers reveal findings on restricted lineage of iPS cells

Adult cells that have been reprogrammed into induced pluripotent stem cells (iPS cells) do not completely let go of their past, perhaps limiting their ability to function as a less controversial alternative to embryonic stem cells for basic research and cell replacement therapies, according to researchers at Children's Hospital Boston, John Hopkins University and their colleagues

20 Jul 2010

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Here are highlights from the July issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required.

20 Jul 2010

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

Mother’s obesity surgery may cause vitamin deficiencies in children

Biliopancreatic diversion surgery for morbid obesity is known to cause multiple vitamin deficiencies that may worsen during pregnancy. In the June issue of the Journal of AAPOS, the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus, a group of Australian clinicians report a child who was born blind as a result of Vitamin A deficiency caused by his mother's obesity surgery.

17 Jul 2010

New research reports evaluating nephrology market in Europe released

BioTrends Research Group, Inc. has released two new syndicated market research reports evaluating the nephrology market in Europe. The reports, TreatmentTrends: Renal Anemia and TreatmentTrends: Bone and Mineral Metabolism, are derived from the responses of over 200 European nephrologists polled in May and June, 2010 regarding their approach to managing renal anemia and bone and mineral disturbances in their dialysis and chronic kidney disease patients.

16 Jul 2010

An overview of heart palpitations from Mayo Clinic

Almost everyone feels occasional heart palpitations -- a change in the heart's rhythm. Palpitations range from what feels like a skip, flip or bump in the heart's rhythm to a sustained, racing heartbeat.

16 Jul 2010

High blood pressure, diabetes leads to CKD

People with diabetes and high blood pressure need to take care of their kidneys. According to the July issue of Mayo Clinic Women's HealthSource, chronic kidney disease (CKD) is a growing problem in the United States. The most common causes are diabetes and high blood pressure

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

This week, nearly 4,000 scientists from around the world gathered to report and discuss the latest advances in research on treatments, risk factors, and diagnosis for the health epidemic of the 21st century – Alzheimer's disease – at the Alzheimer's Association's 2010 International Conference on Alzheimer's Disease in Honolulu.

15 Jul 2010

Ligand Pharmaceuticals announces launch of redesigned Web site

Ligand Pharmaceuticals Incorporated announces the launch of its completely redesigned Web site: www.ligand.com. The new Web site is designed as a comprehensive resource for investors, prospective corporate partners and the life science community to learn more about Ligand's business model, robust pipeline, high-profile partnerships and innovative technology.

15 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

Gene therapy represents safe alternative to current cures for blood disorder β-thalassemia

Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.

14 Jul 2010

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

Having Alzheimer's disease may increase the risk of getting other potentially disabling health conditions, including seizures and anemia, according to new research presented today at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu, HI.

14 Jul 2010

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

Protalix BioTherapeutics, Inc. announced today that the French regulatory authority has granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.

13 Jul 2010

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

12 Jul 2010

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

Medivir announced today 24-week end-of-treatment interim results from the 5-arm phase 2b response guided PILLAR study in 386 treatment-naïve patients with hepatitis C virus (HCV) genotype-1 (TMC435-C205).

12 Jul 2010

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application for SPRYCEL (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.

12 Jul 2010

Anemia News and Research

Further Reading

Drugs can save African infants' lives

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Affymax completes sale of all auction rate securities held by UBS

Researchers reveal findings on restricted lineage of iPS cells

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Mother’s obesity surgery may cause vitamin deficiencies in children

New research reports evaluating nephrology market in Europe released

An overview of heart palpitations from Mayo Clinic

High blood pressure, diabetes leads to CKD

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

Ligand Pharmaceuticals announces launch of redesigned Web site

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Gene therapy represents safe alternative to current cures for blood disorder β-thalassemia

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News